Literature DB >> 33383062

Detection of engineered T cells in FFPE tissue by multiplex in situ hybridization and immunohistochemistry.

Jocelyn H Wright1, Li-Ya Huang2, Stephanie Weaver2, L Diego Archila3, Megan S McAfee3, Alexandre V Hirayama3, Aude G Chapuis4, Marie Bleakley5, Anthony Rongvaux6, Cameron J Turtle7, R Savanh Chanthaphavong2, Jean S Campbell8, Robert H Pierce9.   

Abstract

Identifying engineered T cells in situ is important to understand the location, persistence, and phenotype of these cells in patients after adoptive T cell therapy. While engineered cells are routinely characterized in fresh tissue or blood from patients by flow cytometry, it is difficult to distinguish them from endogenous cells in formalin-fixed, paraffin-embedded (FFPE) tissue biopsies. To overcome this limitation, we have developed a method for characterizing engineered T cells in fixed tissue using in situ hybridization (ISH) to the woodchuck hepatitis post-transcriptional regulatory element (WPRE) common in many lentiviral vectors used to transduce chimeric antigen receptor T (CAR-T) and T cell receptor T (TCR-T) cells, coupled with alternative permeabilization conditions that allows subsequent multiplex immunohistochemical (mIHC) staining within the same image. This new method provides the ability to mark the cells by ISH, and simultaneously stain for cell-associated proteins to immunophenotype CAR/TCR modified T cells within tumors, as well as assess potential roles of these cells in on-target/off-tumor toxicity in other tissue.
Copyright © 2020 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  CAR-T; Immunohistochemistry; Immunophenotyping; TCR-T; WPRE; in situ hybridization

Mesh:

Substances:

Year:  2020        PMID: 33383062      PMCID: PMC7979489          DOI: 10.1016/j.jim.2020.112955

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  38 in total

1.  Woodchuck hepatitis virus posttranscriptional regulatory element enhances expression of transgenes delivered by retroviral vectors.

Authors:  R Zufferey; J E Donello; D Trono; T J Hope
Journal:  J Virol       Date:  1999-04       Impact factor: 5.103

2.  Action of saponin on biological cell membranes.

Authors:  A D BANGHAM; R W HORNE; A M GLAUERT; J T DINGLE; J A LUCY
Journal:  Nature       Date:  1962-12-08       Impact factor: 49.962

Review 3.  Treating cancer with genetically engineered T cells.

Authors:  Tristen S Park; Steven A Rosenberg; Richard A Morgan
Journal:  Trends Biotechnol       Date:  2011-06-12       Impact factor: 19.536

4.  A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma.

Authors:  Donald M O'Rourke; MacLean P Nasrallah; Arati Desai; Jan J Melenhorst; Keith Mansfield; Jennifer J D Morrissette; Maria Martinez-Lage; Steven Brem; Eileen Maloney; Angela Shen; Randi Isaacs; Suyash Mohan; Gabriela Plesa; Simon F Lacey; Jean-Marc Navenot; Zhaohui Zheng; Bruce L Levine; Hideho Okada; Carl H June; Jennifer L Brogdon; Marcela V Maus
Journal:  Sci Transl Med       Date:  2017-07-19       Impact factor: 17.956

5.  Permeabilization of cell membranes.

Authors:  Maria Célia Jamur; Constance Oliver
Journal:  Methods Mol Biol       Date:  2010

6.  Saponin treatment for in situ hybridization maintains good morphological preservation.

Authors:  M Yamawaki; A Zurbriggen; A Richard; M Vandevelde
Journal:  J Histochem Cytochem       Date:  1993-01       Impact factor: 2.479

7.  Activation of CAR and non-CAR T cells within the tumor microenvironment following CAR T cell therapy.

Authors:  Pei-Hsuan Chen; Mikel Lipschitz; Jason L Weirather; Caron Jacobson; Philippe Armand; Kyle Wright; F Stephen Hodi; Zachary J Roberts; Stuart A Sievers; John Rossi; Adrian Bot; William Go; Scott J Rodig
Journal:  JCI Insight       Date:  2020-06-18

8.  Development of T-cell immunotherapy for hematopoietic stem cell transplantation recipients at risk of leukemia relapse.

Authors:  Robson G Dossa; Tanya Cunningham; Daniel Sommermeyer; Indira Medina-Rodriguez; Melinda A Biernacki; Kimberly Foster; Marie Bleakley
Journal:  Blood       Date:  2017-10-19       Impact factor: 25.476

9.  Preclinical Development and Clinical-Scale Manufacturing of HIV Gag-Specific, LentivirusModified CD4 T Cells for HIV Functional Cure.

Authors:  Haishan Li; Tyler Lahusen; Lingzhi Xiao; Nidal Muvarak; Jana Blazkova; Tae-Wook Chun; C David Pauza
Journal:  Mol Ther Methods Clin Dev       Date:  2020-05-03       Impact factor: 6.698

10.  Systemic and local immunity following adoptive transfer of NY-ESO-1 SPEAR T cells in synovial sarcoma.

Authors:  Indu Ramachandran; Daniel E Lowther; Rebecca Dryer-Minnerly; Ruoxi Wang; Svetlana Fayngerts; Daniel Nunez; Gareth Betts; Natalie Bath; Alex J Tipping; Luca Melchiori; Jean-Marc Navenot; John Glod; Crystal L Mackall; Sandra P D'Angelo; Dejka M Araujo; Warren A Chow; George D Demetri; Mihaela Druta; Brian A Van Tine; Stephan A Grupp; Albiruni R Abdul Razak; Breelyn Wilky; Malini Iyengar; Trupti Trivedi; Erin Van Winkle; Karen Chagin; Rafael Amado; Gwendolyn K Binder; Samik Basu
Journal:  J Immunother Cancer       Date:  2019-10-24       Impact factor: 12.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.